AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 121 min read$CMND

HRT FINANCIAL LP purchased $330K of CMND

HRT FINANCIAL LP purchased 2,159,052 shares of Clearmind Medicine Inc. (CMND) at $0.15 ($0.33M total) on 2026-06-10.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 12, 2026, 8:28 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDBullishLow
01

Why it matters

The newest fact is the disclosed purchase size, price ($0.1530/share), and post-transaction holdings for a 10% owner, which can modestly influence sentiment but lacks fundamental new information.

02

Market read

CMND receives a fresh ownership-increase datapoint from a large holder, which may attract short-term attention but is unlikely to drive a durable repricing alone.

03

What to watch

The filing does not disclose intent, valuation rationale, or whether the buy changes future behavior; traders should watch for subsequent Form 4s or company catalysts.

Relevance 5/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-12 (purchase dated 2026-06-10)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

HRT Financial LP (10% owner) filed an SEC Form 4 open-market purchase of 2,159,052 CMND shares on 2026-06-10.

Expected impact

Near-term impact likely limited; any effect would be sentiment-driven and may fade unless followed by additional disclosures.

Evidence & confidence

Form 4 insider/institutional buying can support sentiment, but the article provides no new company-specific operating/regulatory/financial development beyond the transaction details.

Market effects

Sector

No sector-level read-through; this is a single-issuer ownership transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Open-market buys can be routine (e.g., liquidity/portfolio rebalancing) and may not reflect a new thesis; without a 10b5-1 plan, it still may be non-informational.

Key entities

  • issuer
    Clearmind Medicine Inc.

    Subject of the Form 4 disclosure; ticker CMND.

  • 10% owner
    HRT Financial LP

    Reported open-market purchase of CMND shares; filed the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMND insider trading history →

Related articles

SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min
MAY 29
$CMNDMedAI 9/10

Clearmind Medicine Shares Jump 47% After Japan Patent Filing For Depression Treatment

Clearmind Medicine Inc. (CMND) shares rose 46.72% to $3.59 on Friday after the company said a Japanese patent application was published covering compositions using 5-Methoxy-2-aminoindan (MEAI) for depression treatment. The filing, the company said, adds to its intellectual property portfolio for non-hallucinogenic neuroplastogen-derived therapeutics. Volume was 41.05 million shares versus 612,955 average.

rttnews.com3 min